After administration of the coumarin anticoagulant racemic warfarin to normal humans, seven fluorescent compounds were chromatographically separated from extracts of their urine. Four of these were identified using mass spectrometry, thin-layer chromatography, and ultraviolet absorption spectroscopy. One metabolic pathway, reduction of the acetonyl side chain of warfarin, resulted in the formation of a second asymmetric carbon atom, and two diastereoisomer alcohols were identified. These warfarin alcohols are structurally similar to pharmacologically active coumarin derivatives. They have not been reported in animal studies. In addition, 6-and 7-hydroxywarfarin were identified. These are the first studies to document the metabolic fate of warfarin in the normal human. A B S T R A C T After administration of the coumarin anticoagulant racemic warfarin to normal humans, seven fluorescent compounds were chromatographically separated from extracts of their urine. Four of these were identified using mass spectrometry, thin-layer chromatography, and ultraviolet absorption spectroscopy. One metabolic pathway, reduction of the acetonyl side chain of warfarin, resulted in the formation of a second asymmetric carbon atom, and two diastereoisomer alcohols were identified. These warfarin alcohols are structurally similar to pharmacologically active coumarin derivatives. They have not been reported in animal studies. In addition, 6-and 7-hydroxywarfarin were identified. These are the first studies to document the metabolic fate of warfarin in the normal human.
INTRODUCTION
In the 18 yr that have elapsed since its introduction for clinical use, warfarin, rac-(3-(a-acetonylbenzyl)-4-hydroxycoumarin), has become the oral anticoagulant most frequently employed in this country. Despite this extensive experience, major difficulties are still encountered in attempts to maintain stable hypoprothrombinemia. The mechanism by which a hemorrhagic diathesis results from the same drug dose which may also produce acceptable anticoagulation remains, in many cases, unexplained. In addition, resistance to warfarin has been observed, and also remains unexplained.
Although warfarin has been the subject of pharmacogenetic investigations and studies of enzyme induction phenomena, these have been limited by the absence of information concerning the metabolism of warfarin in man. Studies of warfarin "metabolism" have been reAn abstract of portions of this work appeared in Clin. Res. 18: 119, 1970 .
Received for publication 24 October 1969. stricted to analyses of data obtained on plasma levels of unmetabolized drug. For these reasons, therefore, it was felt that a detailed investigation of the metabolic fate of warfarin would be worthwhile. Efforts to elucidate the problem employed the following three approaches: thin-layer chromatography, absorption spectroscopy, and mass spectrometry. The data were compared with those obtained with synthetic warfarin derivatives.
METHODS
Sodium warfarin (Coumadin, Endo Laboratories, Inc., Gar- den City, N. Y.) was administered to informed normal volunteers in a single oral dose of 1.5 mg/kg body weight. Single pooled collections of urine were made over the subsequent 3 days. Urine was also collected from patients receiving 5-15 mg of warfarin daily. The samples, without preservative, were frozen for up to 3 months until processed.
Extraction. Since warfarin and similar compounds are organic acids, it was anticipated that, in a mixture of aqueous and organic solvents, they would be soluble in an alkaline aqueous phase, and soluble in the organic phase upon acidification of the aqueous phase. For the initial extraction, the urine (usually about 1000 ml) was transferred to polypropylene containers. The urine was acidified to pH <2 with concentrated hydrochloric acid and an equal volume of organic solvent (n-butanol: ethylenedichloride, 1: 1) was added. After the mixture was agitated for 30 min on a horizontal shaker, the phases were separated by centrifugation. The organic solvent was removed with a transfer pipet, and the extraction was repeated an additional two times. Characterization of compounds. After the third chromatographic purification, the fluorescent band was cut out, moistened with several drops of 0.25 N NaOH, and scraped into a polyethylene tube with a razor blade. Additional NaOH was added to give a total volume of about 1.5 ml. The compound was eluted by shaking the mixture for 10 min on the horizontal shaker. The silica particles suspended in the NaOH were removed by centrifugation at 10,000 g for 10 min. The ultraviolet absorption spectrum of the supernate was determined with a Zeiss PMQ II spectrophotometer (Carl Zeiss, Inc., New York) ; the spectrum was repeated after the addition of two drops of 3 N HCl to the 1 ml cuvette. This acidified sample was then reextracted into N-butanol, as described, and set aside for further chromatographic analysis and determination of its mass spectrum.
The mass spectra of the materials thus isolated were determined on an AEI MS 902 high resolution mass spectrometer, at approximately 200'C, via the direct insertion inlet system. The empirical formulas of the structurally significant ions were established by exact mass measurement.
Synthetic samples of 5-hydroxywarfarin and the aliphatic side chain alcohols of warfarin were prepared in this laboratory. The authors are grateful to Dr. Mark Hermodson and Professor Karl Paul Link of the University of Wisconsin for samples of synthetic 6-, 7-, and 8-hydroxywarfarin. Synthetic materials were dissolved in acetone and chromatographed once before the determination of their ultraviolet absorption spectra. (and the corresponding compound C from the urine) and 6-hydroxywarfarin (and the corresponding compound CY) could be separated from the other coumarin ring hydroxy derivatives of warfarin (Fig. 3) .
Absorption spectroscopy. The ultraviolet absorption spectra obtained for synthetic 7-hydroxy warfarin and compound C were indistinguishable. Both exhibited extinction maxima at 329 and 256 m' in NaOH, and a maximum at 312 after acidification. This hypsochromic shift in acid was characteristic of all the warfarin derivatives studied (Fig. 4) The fragmentation pattern of synthetic 6-and 7-hydroxywarfarin was similiar to that observed for warfarin. From the molecular ion, cleavage of the acyl group gave rise to a base peak ion. This was followed by loss of the phenyl group, leaving the ion representing the coumarin nucleus. The exact mass measurements of these ions differed from the corresponding ions of warfarin only by the increase of 16 mass units due to the addition of an oxygen atom: M = m/e 324 (C19H1605) > m/e 281 (C17HisO4) -4m/e 203 (CuH704). Compound C and compound CY gave rise to ions at the same exact mass as did synthetic 7-and 6-hydroxywarfarin.
The mass spectra of compounds D1 and D2 were dif-910 R. J. Lewis DISCUSSION For each of the three criteria of identity which were employed in this study, ultraviolet absorption spectroscopy, thin-layer chromatography, and mass spectrometry, the data obtained with the metabolite isolated from the urine and the synthetic compound with the structure proposed for that metabolite were indistinguishable.
Bishydroxycoumarin, ethyl biscoumacetate, phenprocoumon, and warfarin are 3-substituted-4-hydroxycoumarins having ultraviolet absorption maxima in NaOH near 310 myA, indicating that the substitutions in these compounds have little effect on the absorption spectrum of the molecule (1) . The maxima at 309 myA observed for compounds D1 and D2 and the synthetic aliphatic side chain alcohols of warfarin are consistent with this observation. The 6-or 8-hydroxy substitutions on the coumarin ring have only a limited effect on the spectrum. Extinction maxima near 302 myA in NaOH have been observed for both of these compounds (2). The exception to this general pattern, the bathochromic shift to 329 my in the absorption spectrum of compound C and-7-hydroxywarfarin, is presumably due to the extension of conjugation resulting from resonance structures such as depicted in Fig. 5 . Although similar resonance structures are at least possible for 5-hydroxywarfarin, their contributions would be minimized by the formation of an intramolecular hydrogen bond between the 4-and 5-hydroxy groups. Such resonance structures are not possible for warfarin, 6-, or 8-hydroxywarfarin.
Mass spectrometry was of great aid in the efforts to identify these compounds. From the viewpoint of the fragmentation pattern, the warfarin molecule could be considered to consist of the following three parts: the acyl group, the phenyl group, and the coumarin nucleus. Structural modifications in any of these parts of the molecule could be detected by changes in the fragmentation pattern and appropriate alterations in the exact mass measurements of the ions.
The fragmentation pattern and exact mass measurement of the ions given compounds C and CY confirmed that these substances were hydroxylated derivatives of HO FIGURE 5 Resonance structures for hydroxywarfarin substituted in the seven position. In NaOH, this type of resonance would extend conjugation and is presumed to account for the distinctive bathochromic shift in the absorption spectrum of 7-hydroxywarfarin.
warfarin. Since the ion at m/e 187 in the mass spectrum of warfarin represented the coumarin nucleus, the occurrence of the ion at m/e 203 (i.e., m/e 187 + 16) in the mass spectrum of compounds C and CY indicated that the oxygen addition was on the coumarin nucleus. Compounds C and CY therefore represented either 5-, 6-, 7-, or 8-hydroxywarfarin. On the basis of mass spectrometry, a distinction between the four coumarin ring hydroxy derivatives was not possible. Definitive identification was then accomplished by comparative thin-layer chromatography with the demonstration that these four could be separated (Fig. 3) . Therefore, compound C was identified as 7-hydroxywarfarin and compound CY was identified as 6-hydroxywarfarin.
The exact mass measurements of the ions given by compounds D1 and D2 confirmed that these were reduced derivatives of warfarin. Loss of the elements of water which was observed in the fragmentation pattern of these compounds suggested further that these were alcohols of warfarin (3). Indistinguishable chromatographic and mass spectral data were obtained with the synthetic alcohols, and therefore compounds D1 and D2 were identified as aliphatic side chain alcohols of warfarin.
The warfarin which was available for these studies was the racemic mixture of R and S isomers (4) . Acetonyl reduction produced a second asymmetric carbon atom (Fig. 1) . For the warfarin alcohols, four configurations (enantiomers RR, RS, SR, and SS) are thus possible. These consist of two pairs of mirror images (RR-SS and RS-SR), and two pairs of diastereoisomers (RR-RS and SS-SR). Although mirror image compounds have identical chromatographic behavior, diastereoisomers can be resolved (5) . The warfarin alcohols, compounds D1 and D2, therefore each represented either RR and SS or RS and SR in unknown proportions.
These data differ somewhat from those obtained in animal studies, but such species differences are well known. Barker (6, 7) reported 6-, 7-, and 8-hydroxywarfarin, in the rat, and Hermodson (8, 9) described 4'-hydroxywarfarin, a pyranocoumarin and either a sulphate (8) (10) , but the pertinence of this observation to the normal human is uncertain.
Species differences have been observed in the metabolism of compounds structurally related to warfarin. Ethylbiscoumacetate metabolism involves hydroxylation in man, but deesterification in the rabbit (11) . The metabolism of courmarin is to 7-hydroxycoumarin in man (12) ; but all six monohydroxy coumarins in the rabbit (13); and hydroxy derivatives and carbon dioxide in the rat (14) . In all these species, cleavage of the heterocyclic ring of coumarin has been demonstrated, a metabolic pathway which is also present in the gastrointestinal microorganisms of these species (15) .
The 6-, 7-, and 8-hydroxy substitutions are without significant pharmacologic activity (in the rat) (8) . Whether this apparent lack of potency of coumarin ring substitutions of warfarin is due to species specificity, is due to decreased protein binding with presumed rapid renal excretion of polar compounds (2), or rather implies that an intact 4-hydroxycoumarin nucleus is necessary for activity (16) is unclear. On the other hand, compounds D1 and D2, the warfarin alcohols, may well be mediators of an anticoagulant effect.
A variety of compounds which are structurally similar to warfarin are pharmacologically effective, whether the substitutions are on the phenyl (e.g., acenocoumarol) or aliphatic (e.g., phenprocoumon) side chains. The warfarin alcohols differ from phenprocoumon only by a hydroxyethyl instead of a methyl group. Phenprocoumon is even more potent, on a molar basis, than warfarin. Although the relative potency of the four warfarin alcohol enantiomers has not yet been established, the S forms of both warfarin (17) and phenprocoumon (18) have been shown to be about five times more potent than the R isomers. It seems reasonable to anticipate that the stereochemical configuration of the warfarin alcohols may be of similar significance in this regard.
The determinants of the relative production of these metabolites are unknown, although genetic influences have been implicated in dicumarol metabolism (19, 20) . Resistance to warfarin has been described in man (10, 21) and animals (22, 23) and has been shown to be an inherited phenotype (10, 22) . The evidence that, after administration of racemic warfarin, only one warfarin enantiomer is converted to a particular metabolite (8) not only emphasizes the stereospecific nature of these reactions but also leads to the speculation that an alteration in a stereospecific enzyme may be responsible for states of unusual warfarin sensitivity or resistance by alterations in the production of a pharmacologically active metabolite.
